195 related articles for article (PubMed ID: 29104067)
1. The application of Quality by Design framework in the pharmaceutical development of dry powder inhalers.
Buttini F; Rozou S; Rossi A; Zoumpliou V; Rekkas DM
Eur J Pharm Sci; 2018 Feb; 113():64-76. PubMed ID: 29104067
[TBL] [Abstract][Full Text] [Related]
2. Particle sizing of pharmaceutical aerosols via direct imaging of particle settling velocities.
Fishler R; Verhoeven F; de Kruijf W; Sznitman J
Eur J Pharm Sci; 2018 Feb; 113():152-158. PubMed ID: 28821437
[TBL] [Abstract][Full Text] [Related]
3. New aspects of developing a dry powder inhalation formulation applying the quality-by-design approach.
Pallagi E; Karimi K; Ambrus R; Szabó-Révész P; Csóka I
Int J Pharm; 2016 Sep; 511(1):151-160. PubMed ID: 27386791
[TBL] [Abstract][Full Text] [Related]
4. Determination of Passive Dry Powder Inhaler Aerodynamic Particle Size Distribution by Multi-Stage Cascade Impactor: International Pharmaceutical Aerosol Consortium on Regulation & Science (IPAC-RS) Recommendations to Support Both Product Quality Control and Clinical Programs.
Mitchell JP; Stein SW; Doub W; Goodey AP; Christopher JD; Patel RB; Tougas TP; Lyapustina S
AAPS PharmSciTech; 2019 May; 20(5):206. PubMed ID: 31147791
[TBL] [Abstract][Full Text] [Related]
5. Dry powder inhalers: An overview of the in vitro dissolution methodologies and their correlation with the biopharmaceutical aspects of the drug products.
Velaga SP; Djuris J; Cvijic S; Rozou S; Russo P; Colombo G; Rossi A
Eur J Pharm Sci; 2018 Feb; 113():18-28. PubMed ID: 28887232
[TBL] [Abstract][Full Text] [Related]
6. Dry powder inhalers in COPD, lung inflammation and pulmonary infections.
Muralidharan P; Hayes D; Mansour HM
Expert Opin Drug Deliv; 2015 Jun; 12(6):947-62. PubMed ID: 25388926
[TBL] [Abstract][Full Text] [Related]
7. A review of co-milling techniques for the production of high dose dry powder inhaler formulation.
Lau M; Young PM; Traini D
Drug Dev Ind Pharm; 2017 Aug; 43(8):1229-1238. PubMed ID: 28367654
[TBL] [Abstract][Full Text] [Related]
8. Powder, capsule and device: An imperative ménage à trois for respirable dry powders.
Schoubben A; Blasi P; Giontella A; Giovagnoli S; Ricci M
Int J Pharm; 2015 Oct; 494(1):40-8. PubMed ID: 26255220
[TBL] [Abstract][Full Text] [Related]
9. Aerodynamic factors responsible for the deaggregation of carrier-free drug powders to form micrometer and submicrometer aerosols.
Longest PW; Son YJ; Holbrook L; Hindle M
Pharm Res; 2013 Jun; 30(6):1608-27. PubMed ID: 23471640
[TBL] [Abstract][Full Text] [Related]
10. The Impact of Inspiratory Flow Rate on Drug Delivery to the Lungs with Dry Powder Inhalers.
Weers J; Clark A
Pharm Res; 2017 Mar; 34(3):507-528. PubMed ID: 27738953
[TBL] [Abstract][Full Text] [Related]
11. Formulation techniques for high dose dry powders.
Brunaugh AD; Smyth HDC
Int J Pharm; 2018 Aug; 547(1-2):489-498. PubMed ID: 29778822
[TBL] [Abstract][Full Text] [Related]
12. Tuning aerosol performance using the multibreath Orbital® dry powder inhaler device: controlling delivery parameters and aerosol performance via modification of puck orifice geometry.
Zhu B; Young PM; Ong HX; Crapper J; Flodin C; Qiao EL; Phillips G; Traini D
J Pharm Sci; 2015 Jul; 104(7):2169-76. PubMed ID: 25931324
[TBL] [Abstract][Full Text] [Related]
13. Low powder mass filling of dry powder inhalation formulations.
Eskandar F; Lejeune M; Edge S
Drug Dev Ind Pharm; 2011 Jan; 37(1):24-32. PubMed ID: 20738180
[TBL] [Abstract][Full Text] [Related]
14. Formulating powder-device combinations for salmeterol xinafoate dry powder inhalers.
Hassoun M; Ho S; Muddle J; Buttini F; Parry M; Hammond M; Forbes B
Int J Pharm; 2015 Jul; 490(1-2):360-7. PubMed ID: 25987210
[TBL] [Abstract][Full Text] [Related]
15. The nanoscale in pulmonary delivery. Part 2: formulation platforms.
Rogueda PG; Traini D
Expert Opin Drug Deliv; 2007 Nov; 4(6):607-20. PubMed ID: 17970664
[TBL] [Abstract][Full Text] [Related]
16. Dry powder inhalers (DPIs)--a review of device reliability and innovation.
Islam N; Gladki E
Int J Pharm; 2008 Aug; 360(1-2):1-11. PubMed ID: 18583072
[TBL] [Abstract][Full Text] [Related]
17. Electrostatics of pharmaceutical inhalation aerosols.
Kwok PC; Chan HK
J Pharm Pharmacol; 2009 Dec; 61(12):1587-99. PubMed ID: 19958580
[TBL] [Abstract][Full Text] [Related]
18. Pulmonary drug delivery by powder aerosols.
Yang MY; Chan JG; Chan HK
J Control Release; 2014 Nov; 193():228-40. PubMed ID: 24818765
[TBL] [Abstract][Full Text] [Related]
19. Coupled in silico platform: Computational fluid dynamics (CFD) and physiologically-based pharmacokinetic (PBPK) modelling.
Vulović A; Šušteršič T; Cvijić S; Ibrić S; Filipović N
Eur J Pharm Sci; 2018 Feb; 113():171-184. PubMed ID: 29054499
[TBL] [Abstract][Full Text] [Related]
20. Heat-Stable Dry Powder Oxytocin Formulations for Delivery by Oral Inhalation.
Fabio K; Curley K; Guarneri J; Adamo B; Laurenzi B; Grant M; Offord R; Kraft K; Leone-Bay A
AAPS PharmSciTech; 2015 Dec; 16(6):1299-306. PubMed ID: 25776985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
